Chondrosarcoma Deep Research Notes

Scope

• Target disease file: kb/disorders/Chondrosarcoma.yaml
• Disease anchor: MONDO:0008977 chondrosarcoma
• Curation objective: one disease-level cancer mechanism graph for chondrosarcoma, with subtype facets grounded to ontology terms where available

Modeling Decisions Applied From Issue #1198

• The dismech entry is the mechanism-graph unit, so this curation stays in a single Chondrosarcoma.yaml file rather than splitting conventional, dedifferentiated, mesenchymal, clear cell, periosteal, primary central, or secondary peripheral disease into separate pages.
• disease_term is MONDO-first: MONDO:0008977 is the graph anchor.
• subtype_term is used only where MONDO offers the relevant subclass:
• MONDO:0005013 dedifferentiated chondrosarcoma
• MONDO:0006853 mesenchymal chondrosarcoma
• MONDO:0003684 clear cell chondrosarcoma
• MONDO:0003680 periosteal chondrosarcoma
• Subtypes are modeled as flat facet axes rather than as separate disease pages:
• Histology: Conventional, Dedifferentiated, Mesenchymal, Clear Cell
• Surface origin: Periosteal
• Tumor origin / predisposition context: Primary Central, Secondary Peripheral
• NCIT was added routinely where the current schema can represent oncology specificity:
• Disease/subtype-level grounding through histopathology.finding_term
• Treatment grounding through treatment_term
• The current schema does not expose a disease-level or subtype-level ncit_mappings slot. Because of that schema constraint, NCIT specificity was carried in histopathology and treatment sections instead of an impossible direct mapping block.
• MAXO was not used for the core oncology interventions because NCIT provides materially better cancer-specific granularity here (Definitive Surgical Resection, En Bloc Resection, Chemotherapy, Targeted Therapy).

Subtype Grounding Chosen For The Disease Slice

Mechanism Selection Rationale

The mechanism nodes were kept atomic rather than bundled:

1. IDH1/IDH2 Neomorphic Enzyme Activity
2. D-2-Hydroxyglutarate Accumulation
3. IDH-Linked DNA Methylation Dysregulation
4. COL2A1 Matrix Gene Disruption
5. TP53 Dysfunction
6. Cell Cycle Activation
7. HEY1::NCOA2 Fusion Oncogenic Program
8. EXT1/EXT2 Heparan Sulfate Polymerization Failure
9. Secondary Peripheral Malignant Transformation

This structure preserves causal order:

• mutant IDH enzymes -> 2-HG accumulation -> methylation dysregulation
• TP53 dysfunction -> proliferative progression / cell cycle activation
• EXT-associated heparan sulfate failure -> osteochondroma predisposition -> malignant peripheral transformation

Key PMID Evidence Used

Disease definition and subtype structure

• PMID:34742483
• Quote: Chondrosarcomas are heterogeneous matrix-producing cartilaginous neoplasms with variable clinical behavior.
• Quote: Subtypes include conventional (75%), dedifferentiated (10%), clear cell (2%), mesenchymal (2%), and periosteal chondrosarcoma (<1%).
• Use: disease-level description and flat histologic subtype axis

Primary central disease and IDH biology

• PMID:30296521
• Quote: Central conventional chondrosarcoma is the most common subtype and is associated with isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) gene mutations in 50% to 60% of cases.

• Use: Primary Central subtype plus IDH1/IDH2 Neomorphic Enzyme Activity

• PMID:32208957

• Quote: Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG).
• Quote: Plasma 2-HG levels decreased substantially in all patients (range, 14%-94.2%), to levels seen in healthy individuals.
• Quote: In patients with chondrosarcoma, ivosidenib showed minimal toxicity, substantial 2-HG reduction, and durable disease control.

• Use: IDH metabolic node chain plus targeted therapy

• PMID:31604924

• Quote: Here we use multi-omics molecular profiles from a series of cartilage tumors and find an mRNA classification that identifies two subtypes of chondrosarcomas defined by a balance in tumor differentiation and cell cycle activation.
• Quote: Finally, DNA methylation is associated with IDH mutations.
• Use: cell-cycle and methylation nodes

Matrix disruption and aggressive progression

• PMID:23770606
• Quote: We identified hypermutability of the major cartilage collagen gene COL2A1, with insertions, deletions and rearrangements identified in 37% of cases.
• Quote: The patterns of mutation were consistent with selection for variants likely to impair normal collagen biosynthesis.

• Use: COL2A1 Matrix Gene Disruption

• PMID:37747813

• Quote: TP53 mutation was the next most prevalent (41.9%) and is associated with worse overall survival and metastasis-free survival in both univariate and multivariate analyses.

• Use: TP53 Dysfunction

• PMID:41391500

• Quote: Preclinical research and analyses of patient tumor samples have identified several molecular mechanisms driving chondrosarcoma development and progression, including mutations in isocitrate dehydrogenases types 1 and 2 (IDH1/2) and TP53, hyperactivation of protumorigenic signaling pathways, and programmed cell death ligand 1 (PD-L1) expression.
• Quote: Wide surgical resection remains the standard treatment for localized disease and can be curative; however, effective therapies for unresectable or metastatic chondrosarcoma are needed.
• Use: disease overview, TP53 context, definitive surgery

Mesenchymal subtype

• PMID:35672279
• Quote: Mesenchymal chondrosarcoma (MCS) is a rare translocation-associated sarcoma, driven by a canonical HEY1::NCOA2 fusion.
• Quote: The tumors typically have a biphasic phenotype of primitive small blue round cells intermixed with hyaline cartilage.
• Use: mesenchymal subtype grounding plus fusion-driven mechanism

Clear cell subtype

• PMID:37805864
• Quote: Clear cell chondrosarcoma (CCC), an extremely rare primary bone tumor, is currently classified by the World Health Organization as a low-grade malignant cartilaginous neoplasm.
• Quote: Unlike conventional chondrosarcoma, CCC has a predilection for the epiphysis of long bones and often displays radiologic features reminiscent of chondroblastoma.
• Quote: Histologically, the process is characterized by infiltrative lobules and sheets of round to oval cells with abundant cleared cytoplasm and well-defined cell borders associated with trabecula of osteoid and woven bone, scattered osteoclasts, and foci of conventional low-grade chondrosarcoma in about one-half of cases.
• Quote: The recommended treatment is wide operative resection.
• Use: clear cell subtype grounding, morphology, surgery context

Secondary peripheral transformation and EXT biology

• PMID:18271966
• Quote: The most important complication is malignant transformation of osteochondroma towards secondary peripheral chondrosarcoma, which is estimated to occur in 0.5-5%.
• Quote: In almost 90% of MO patients germline mutations in the tumour suppressor genes EXT1 or EXT2 are found.
• Quote: The EXT genes encode glycosyltransferases, catalyzing heparan sulphate polymerization.
• Quote: For secondary peripheral chondrosarcoma, en-bloc resection of the lesion and its pseudocapsule with tumour-free margins, preferably in a bone tumour referral centre, should be performed.
• Use: Secondary Peripheral facet, EXT mechanism, malignant transformation node, and subtype-specific surgery

Dedifferentiated subtype and clinical phenotype

• PMID:34734747
• Quote: Dedifferentiated chondrosarcomas are aggressive variants of chondrosarcoma, associated with poor outcomes.
• Quote: Tumor biphasism is the norm.
• Quote: Radiologically, large soft tissue masses with bony destruction predominate.
• Quote: Surgical resection forms the standard of care for localized disease.
• Quote: These rare tumors affect middle-aged individuals and present with pain and swelling in the affected site.
• Use: dedifferentiated subtype grounding, soft tissue mass phenotype, pain phenotype, surgery

Systemic therapy heterogeneity

• PMID:30082492
• Quote: Patients diagnosed with mesenchymal chondrosarcoma were all treated with multidrug chemotherapy, and the mean PFS was 6.7 months.
• Quote: Prospective studies need to be conducted based on preclinical work to develop a uniform regimen to treat advanced chondrosarcoma patients according to the diagnosed subtype and improve survival.
• Use: subtype-dependent chemotherapy context

Open Limits / Known Constraints

• The current schema cannot express direct NCIT mappings on disease_term or subtype_term, so those oncology mappings were represented indirectly through histopathology and treatment slots.
• Conventional, primary central, and secondary peripheral classifications overlap in real tumors. They were kept as flat facets instead of nested subtype pages to avoid falsely implying separate mechanism graphs.
• No separate disease files were created for dedifferentiated, mesenchymal, clear cell, or periosteal variants because the curation target for issue #1204 is the disease-level chondrosarcoma slice, with subtype-specific mechanisms embedded inside one graph.